石药集团(01093)：GLP-1/GIP受体双偏向性激动多肽长效注射液在中国获临床试验批准_老虎社区_美港股上老虎

石药集团(01093)：GLP-1/GIP受体双偏向性激动多肽长效注射液在中国获临床试验批准

智通财经03-20

智通财经APP讯，石药集团(01093)发布公告，本集团开发的GLP-1/GIP受体双偏向性激动多肽长效注射液(SYH2082注射液)(SYH2082)已获中国国家药品监督管理局批准，可在中国开展临床试验。 SYH2082亦已于2026年2月获美国食品药品监督管理局(FDA)批准，可在美国开展临床试验。SYH2082有望成为临床开发阶段具领先潜力的长效GLP-1/GIP受体双重偏向性激动剂，每月给...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2620878247?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-20 18:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620878247","market":"fut","top_or_hot":-1,"title":"石药集团(01093)：GLP-1/GIP受体双偏向性激动多肽长效注射液在中国获临床试验批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，石药集团(01093)发布公告，本集团开发的GLP-1/GIP受体双偏向性激动多肽长效注射液(SYH2082注射液)(SYH2082)已获中国国家药品监督管理局批准，可在中国开展临床试验。 SYH2082亦已于2026年2月获美国食品药品监督管理局(FDA)批准，可在美国开展临床试验。SYH2082有望成为临床开发阶段具领先潜力的长效GLP-1/GIP受体双重偏向性激动剂，每月给...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1416658.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药集团(01093)：GLP-1/GIP受体双偏向性激动多肽长效注射液在中国获临床试验批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药集团(01093)：GLP-1/GIP受体双偏向性激动多肽长效注射液在中国获临床试验批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-20 18:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1416658.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，石药集团(01093)发布公告，本集团开发的GLP-1/GIP受体双偏向性激动多肽长效注射液(SYH2082注射液)(SYH2082)已获中国国家药品监督管理局批准，可在中国开展临床试验。 SYH2082亦已于2026年2月获美国食品药品监督管理局(FDA)批准，可在美国开展临床试验。SYH2082有望成为临床开发阶段具领先潜力的长效GLP-1/GIP受体双重偏向性激动剂，每月给...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1416658.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1416658.html","article_id":"2620878247","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620878247","pubTimestamp":1774002289,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，石药集团 发布公告，本集团开发的GLP-1/GIP受体双偏向性激动多肽长效注射液已获中国国家药品监督管理局批准，可在中国开展临床试验。SYH2082有望成为临床开发阶段具领先潜力的长效GLP-1/GIP受体双重偏向性激动剂，每月给药一次。依托本集团的长效制剂技术平台，SYH2082可实现月度给药，提高患者依从性与用药便捷性。在毒理学研究中， SYH2082的耐受性良好，未观察到显著不良反应。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1515":"抗疫概念","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","BK4590":"PTP","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","01093":"石药集团","IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","GLP":"Global Partners Lp","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","BK1191":"制药","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","BK4144":"石油与天然气的储存和运输","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD"},"translate_title":"CSPC (01093): GLP-1/GIP receptor bias agonist peptide long-acting injection obtained clinical trial approval in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1.5,"01093":1.5},"content_text":"智通财经APP讯，石药集团(01093)发布公告，本集团开发的GLP-1/GIP受体双偏向性激动多肽长效注射液(SYH2082注射液)(SYH2082)已获中国国家药品监督管理局批准，可在中国开展临床试验。 SYH2082亦已于2026年2月获美国食品药品监督管理局(FDA)批准，可在美国开展临床试验。SYH2082有望成为临床开发阶段具领先潜力的长效GLP-1/GIP受体双重偏向性激动剂，每月给药一次。依托本集团的长效制剂技术平台，SYH2082可实现月度给药，提高患者依从性与用药便捷性。SYH2082可选择性激活cAMP通路，降低β-arrestin募集，从而减少受体内吞及脱敏，提升药效并延长作用持续时间。同时，SYH2082结合长半衰期修饰平台技术和长效制剂平台技术，旨在实现给药间隔内的持续减重。在临床前研究中，SYH2082在长效减重及维持方面较同类上市产品表现出更优的疗效，且支持每月一次的用药方案。在毒理学研究中， SYH2082的耐受性良好，未观察到显著不良反应。本次获批的临床适应症为肥胖或超重合并至少一种体重相关合并症人群的体重管理。此外，SYH2082亦具备改善成人2型糖尿病(T2DM)患者的血糖控制的潜力，带来临床获益。本次临床试验的获批，是本集团在代谢领域创新长效产品布局的重要成果，为未来更多创新产品的开发奠定坚实基础。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}